Finzati - Logo
RIGL logo

Rigel Pharmaceuticals, Inc.

RIGL • Biotechnology
$0.00
— 0.00 (0.00%)
EarningsLatest report: Mar 31, 2026
HIGHLY FAVORABLE PROFILEExcellentConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$676.25M
Growth
-10.1%
Cash Flow
3/5
Trend
Mostly stable
Evidence
Stable or improving margins · 124.7%Positive revenue growth · 16.9%Positive free cash flow · 4.21Reasonable earnings multiple · 2.1Manageable debt level · 0.14
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 5, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:36 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.00
Change0.00%
Market Cap$676.25M
52W Range18.20 - 52.24
Beta1.18
Gross Margin93.33%
Oper. Margin42.63%
Profit Margin124.72%
Debt/Eq0.14
Current Ratio2.42
Quick Ratio2.30
Revenue 5Y-10.07%

Investment DNA

How strong this company looks for long-term investors

89
out of 100
Business Quality
Margins, moat, returns
90/100
Financial Strength
Debt, cash, stability
95/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
90/100
Why this score▼
Stable or improving margins · 124.7%Positive revenue growth · 16.9%Positive free cash flow · 4.21Reasonable earnings multiple · 2.1Manageable debt level · 0.14Healthy liquidity · 2.42

Analyst view

Analyst sentiment and price target

Analyst sentiment
No vote count available
Bullish
0
Hold
0
Bearish
0
Price Target
2026-06-25
Low
$2.00
Mean
$27.33
Median
$38.00
High
$42.00

Company Overview

IPO: 11/29/2000
Industry: Biotechnology
P/B i: 1.97
Debt / Equity i: 0.14
Operating Margin: 42.63%
Net Margin: 1.25%
ROE i: -
ROIC: -

Financial Health

Score19 / 20
Debt / Equity: 0.14
Current Ratio: 2.42
Quick Ratio: 2.30
Status: Strong

Insider Transactions

Recent executive and insider activity

Ali-Jackson Kamil
Transaction: 06/22/2026
SELL
Change
-2,500
Price
$35.00
Filing
06/24/2026
Type
SELL
Schorno Dean L
Transaction: 06/17/2026
BUY
Change
+7,394
Price
$22.49
Filing
06/22/2026
Type
BUY
Santos David A
Transaction: 06/17/2026
BUY
Change
+7,394
Price
$22.49
Filing
06/22/2026
Type
BUY